ID: ALA3392650

Max Phase: Preclinical

Molecular Formula: C17H22N2O6S2

Molecular Weight: 414.51

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CC1(C)SCCN(S(=O)(=O)c2ccc(OCC#CCO)cc2)C1C(=O)NO

Standard InChI:  InChI=1S/C17H22N2O6S2/c1-17(2)15(16(21)18-22)19(9-12-26-17)27(23,24)14-7-5-13(6-8-14)25-11-4-3-10-20/h5-8,15,20,22H,9-12H2,1-2H3,(H,18,21)

Standard InChI Key:  MAVDNGWEBZTACC-UHFFFAOYSA-N

Associated Targets(Human)

Matrix metalloproteinase 3 3433 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

ADAM17 3550 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

ADAM10 375 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase-1 7046 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

ADAM9 81 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Matrix metalloproteinase 9 6779 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 414.51Molecular Weight (Monoisotopic): 414.0919AlogP: 0.45#Rotatable Bonds: 5
Polar Surface Area: 116.17Molecular Species: NEUTRALHBA: 7HBD: 3
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.70CX Basic pKa: CX LogP: 0.54CX LogD: 0.52
Aromatic Rings: 1Heavy Atoms: 27QED Weighted: 0.36Np Likeness Score: -0.73

References

1. PubChem BioAssay data set, 
2.  (2015)  N-[2-hydroxycarbamoyl-2-(piperazinyl) ethyl] benzamide compounds, their preparation and their use as TACE inhibitors,